Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, July 19th. Investors of record on Tuesday, August 13th will be given a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.75%. The ex-dividend date of this dividend is Monday, August 12th. View Allergan's Dividend History.

Allergan declared that its board has authorized a stock buyback plan on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its stock is undervalued.

Allergan plc (NYSE:AGN) posted its earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $4.34 by $0.04. The business earned $4.09 billion during the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The business's quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.42 earnings per share. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 analysts have issued 12-month price targets for Allergan's stock. Their forecasts range from $144.95 to $255.00. On average, they anticipate Allergan's share price to reach $179.15 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News articles about AGN stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Allergan.

Allergan saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average daily volume of 3,600,000 shares, the short-interest ratio is currently 2.9 days. Currently, 3.2% of the company's shares are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by many different of retail and institutional investors. Top institutional investors include Metropolis Capital Ltd (0.05%), State of Alaska Department of Revenue (0.02%), Havens Advisors LLC (0.02%), Alpine Group USVI LLC (0.01%), Gibraltar Capital Management Inc. (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Metropolis Capital Ltd, Nelson Van Denburg & Campbell Wealth Management Group LLC, Gofen & Glossberg LLC IL, Welch & Forbes LLC, Arden Trust Co, Gibraltar Capital Management Inc., Crossmark Global Holdings Inc. and Bremer Bank National Association. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue, Cerebellum GP LLC, Cerebellum GP LLC, Legacy Private Trust Co., Clarus Wealth Advisors and Berkshire Asset Management LLC PA. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $168.94.

Allergan has a market capitalization of $55.42 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]